Seagen reported second quarter revenue of $498 million, up 28%, beating analyst expectations. The company also recently reported “positive” early data from a trial testing its drug Padcev in combination with Merck’s Keytruda for advanced urothelial cancer. In a call

Ali Ansary (left) Ozette CEO and Greg Finak, chief technology officer. (Ozette Photos) The news: Single cell analysis startup Ozette Technologies, with deep roots in the Seattle academic and startup community, has raised $26 million. The company’s tools enable its

Intrinsic Medicine CEO Alex Martinez. (Intrinsic Photo) A quiet Seattle biotech company, Intrinsic Medicine, filed to go public in April but withdrew its plans yesterday, according to a regulatory filing. Intrinsic Medicine is developing sugar-based molecules matching those found in

Seattle area biotech company Seagen released early data on a trial of its drug Padcev combined with Merck’s Keytruda in patients with urothelial tumors. An analyst with SVB Securities told Endpoints News the data “came in above what we viewed